The T cell infiltrates that are formed in human cancers are a modifier of natural disease
progression and also determine the probability of clinical response to cancer …

CD8+ T cells specific for cancer cells are detected within tumours. However, despite their
presence, tumours progress. The clinical success of immune checkpoint blockade and …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Whereas preclinical investigations and clinical studies have established that CD8+ T cells
can profoundly affect cancer progression, the underlying mechanisms are still elusive …

T cells mediate anti-tumor immune responses and are the key target of immune checkpoint
therapy, but they can also promote immune tolerance. A clear understanding of the specific …

Purpose Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer
immune activity and has gained interest in the era of immune checkpoint therapy. Methods …

Clinically relevant immunological biomarkers that discriminate between diverse
hypofunctional states of tumor-associated CD8+ T cells remain disputed. Using multiomics …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Simple Summary Diverse evidence revealed that CD4+ T cells play an important role in
antitumor immunity by promoting or suppressing cytotoxic T cell responses. This review …